Literature DB >> 8999970

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

R J Kowalski1, P Giannakakou, E Hamel.   

Abstract

Epothilones A and B, natural products with minimal structural analogy to taxoids, have effects similar to those of paclitaxel (Taxol(R)) in cultured cells and on microtubule protein, but differ from paclitaxel in retaining activity in multidrug-resistant cells. We examined interactions of the epothilones with purified tubulin and additional cell lines, including a paclitaxel-resistant ovarian carcinoma line with an altered beta-tubulin. The epothilones, like paclitaxel, induced tubulin to form microtubules at low temperatures and without GTP and/or microtubule-associated proteins. The epothilones are competitive inhibitors of the binding of [3H]paclitaxel to tubulin polymers. The apparent Ki values for epothilones A and B were 1.4 and 0.7 microM by Hanes analysis and 0.6 and 0.4 microM by Dixon analysis. In the paclitaxel-sensitive human cell lines we examined, epothilone B had greater antiproliferative activity than epothilone A or paclitaxel, while epothilone A was usually less active than paclitaxel. A multidrug-resistant colon carcinoma line and the paclitaxel-resistant ovarian line retained sensitivity to the epothilones. With Potorous tridactylis kidney epithelial (PtK2) cells examined by indirect immunofluorescence, microtubule bundles appeared more rapidly following epothilone B treatment, and there were different proportions of various mitotic aberrations following treatment with different drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8999970     DOI: 10.1074/jbc.272.4.2534

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  103 in total

Review 1.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Authors:  Jason Konner; Rachel N Grisham; Jae Park; Owen A O'Connor; Gillian Cropp; Robert Johnson; Alison L Hannah; Martee L Hensley; Paul Sabbatini; Svetlana Mironov; Svetlana Miranov; Samuel Danishefsky; David Hyman; David R Spriggs; Jakob Dupont; Carol Aghajanian
Journal:  Invest New Drugs       Date:  2011-11-10       Impact factor: 3.850

3.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice.

Authors:  T C Chou; O A O'Connor; W P Tong; Y Guan; Z G Zhang; S J Stachel; C Lee; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Authors:  David M Peereboom; Jeffrey G Supko; Kathryn A Carson; Tracy Batchelor; Surasak Phuphanich; Glenn Lesser; Tom Mikkelsen; Tom Mikkelson; Joy Fisher; Serena Desideri; Xiaoying He; Stuart A Grossman
Journal:  J Neurooncol       Date:  2010-05-07       Impact factor: 4.130

5.  A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Authors:  Hui Huang; Michael Menefee; Maureen Edgerly; Sen Zhuang; Herb Kotz; Marianne Poruchynsky; Lyn Mickley Huff; Susan Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

6.  Metronomic dosing enhances the anti-angiogenic effect of epothilone B.

Authors:  Mark W Stalder; Catherine T Anthony; Eugene A Woltering
Journal:  J Surg Res       Date:  2009-12-30       Impact factor: 2.192

7.  Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.

Authors:  Thota Ganesh; Chao Yang; Andrew Norris; Tom Glass; Susan Bane; Rudravajhala Ravindra; Abhijit Banerjee; Belhu Metaferia; Shala L Thomas; Paraskevi Giannakakou; Ana A Alcaraz; Ami S Lakdawala; James P Snyder; David G I Kingston
Journal:  J Med Chem       Date:  2007-01-31       Impact factor: 7.446

8.  Design and synthesis of C6-C8 bridged epothilone A.

Authors:  Weiqiang Zhan; Yi Jiang; Peggy J Brodie; David G I Kingston; Dennis C Liotta; James P Snyder
Journal:  Org Lett       Date:  2008-03-21       Impact factor: 6.005

9.  Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity.

Authors:  A L Risinger; J Li; M J Bennett; C C Rohena; J Peng; D C Schriemer; S L Mooberry
Journal:  Cancer Res       Date:  2013-09-18       Impact factor: 12.701

10.  Total synthesis and evaluation of C26-hydroxyepothilone D derivatives for photoaffinity labeling of beta-tubulin.

Authors:  Emily A Reiff; Sajiv K Nair; John T Henri; Jack F Greiner; Bollu S Reddy; Ramappa Chakrasali; Sunil A David; Ting-Lan Chiu; Elizabeth A Amin; Richard H Himes; David G Vander Velde; Gunda I Georg
Journal:  J Org Chem       Date:  2010-01-01       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.